Search Results for "vaccine, MMR"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vaccine, MMR. Results 1 to 4 of 4 total matches.
Adult Immunization
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022 (Issue 1661)
not have evidence of immunity to rubella
should receive a dose of MMR vaccine postpartum,
before discharge ...
The Advisory Committee on Immunization Practices
(ACIP) recommends use of certain vaccines in adults
residing in the US. Routine childhood immunization
has reduced the overall incidence of some of
these vaccine-preventable diseases, but many
adults remain susceptible. Recommendations for
vaccination against COVID-19, seasonal influenza,
and monkeypox and vaccination of travelers have
been reviewed separately.
Dostarlimab (Jemperli) for Endometrial Cancer (online only)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
,
blocking its interaction with PD-L1 and PD-L2 and
restoring T cell antitumor immune responses. dMMR ...
The FDA has granted regular approval to dostarlimabgxly
(Jemperli – GSK), an immune checkpoint
inhibitor, for treatment of adults with mismatch repair
deficient (dMMR) recurrent or advanced endometrial
cancer that has progressed on or following a prior
platinum-containing regimen in any setting and who
are not candidates for curative surgery or radiation.
Dostarlimab received accelerated approval in 2021
for treatment of adults with dMMR recurrent or
advanced endometrial cancer or nonendometrial
solid tumors that progressed on or following prior
treatment and who have no...
Med Lett Drugs Ther. 2023 Apr 3;65(1673):e64-5 doi:10.58347/tml.2023.1673h | Show Introduction Hide Introduction
In Brief: A New Endometrial Cancer Indication for Dostarlimab (Jemperli) (online only)
The Medical Letter on Drugs and Therapeutics • Aug 21, 2023 (Issue 1683)
immune responses. dMMR
tumors are more responsive to PD-1 blockade than
mismatch repair-proficient ...
The immune checkpoint inhibitor dostarlimab-gxly
(Jemperli – GSK) has been approved by the FDA for
use in combination with carboplatin and paclitaxel
for treatment of adults with mismatch repair deficient
(dMMR) or microsatellite instability-high (MSI-H)
primary advanced or recurrent endometrial cancer.
Dostarlimab was recently granted regular approval
for treatment of adults with dMMR recurrent or
advanced endometrial cancer that progressed on
or following a prior platinum-containing regimen in
any setting and who are not candidates for curative
surgery or radiation.
Med Lett Drugs Ther. 2023 Aug 21;65(1683):e138 doi:10.58347/tml.2023.1683f | Show Introduction Hide Introduction
Expanded Table: Some Vaccines for Adults (online only)
The Medical Letter on Drugs and Therapeutics • Oct 17, 2022 (Issue 1661)
during or after
1980 without evidence of
immunity (documentation of
vaccination, laboratory evidence ...